The PRIME trial, a large-scale randomized clinical study funded by the John Black Charitable Foundation and Prostate Cancer UK, was published recently in the prestigious medical journal JAMA. The trial compared traditional three-part multiparametric MRI (mpMRI) scans with an abbreviated two-part biparametric MRI (bpMRI) protocol. Remarkably, the shorter bpMRI scan reduces scan time from 30-40 minutes to just 15-20 minutes, eliminating the need for a contrast dye injection and reducing the requirement for clinical staff intervention during imaging.

MRI technology has transformed prostate cancer diagnosis during the past decade, enabling clinicians to visualize suspicious abnormalities within the prostate gland and better target biopsies to detect significant cancers while avoiding overdiagnosis of indolent disease. The mpMRI procedure typically includes three imaging sequences, one of which involves injecting a gadolinium-based contrast agent to highlight cancerous tissues. However, this contrast phase adds time, cost, and the rare risk of adverse reactions.

Despite the proven benefits of MRI in prostate cancer detection, many men eligible for this diagnostic test fail to receive it, often due to resource limitations in healthcare settings globally. Previous studies have shown that only about one-third of men diagnosed with prostate cancer in the United States underwent an MRI in 2022, while in England and Wales, just 62% of men requiring imaging received it in 2019. These gaps highlight an urgent need to streamline and expand access to prostate MRI.

The PRIME trial enrolled 555 men aged 59 to 70 from 22 hospitals spanning 12 countries, providing a robust and internationally representative dataset. Each participant underwent a full mpMRI scan encompassing all three imaging phases, followed by separate assessments of the shorter biparametric scan images without the contrast-enhanced stage. Subsequent biopsies were performed when clinically indicated to confirm diagnostic accuracy.

Results confirmed the two-part bpMRI scan matched the diagnostic sensitivity of the full mpMRI scan, detecting clinically important prostate cancer in 29% of cases in both scan groups. These findings suggest that the contrast-based third phase may be redundant in many clinical situations, offering an opportunity to safely reduce scan duration and eliminate the need for intravenous contrast without compromising diagnostic accuracy.

Dr Veeru Kasivisvanathan, the trial’s lead investigator from UCL Surgery & Interventional Science and UCLH, emphasized the implications of these findings, noting the global demand for approximately four million prostate MRI scans annually is expected to surge alongside increasing prostate cancer incidence. Reducing scan times and staffing requirements could address systemic bottlenecks, enabling hospitals to accommodate more patients and expedite diagnoses.

From a technical standpoint, the biparametric MRI leverages high-resolution T2-weighted and diffusion-weighted imaging sequences to detect suspicious lesions within the prostate. The omission of dynamic contrast-enhanced imaging streamlines workflow and removes a phase that requires the presence of medical staff, intravenous access, and adds patient discomfort. The study highlights the importance of ensuring that MRI interpretation is conducted by radiologists with specialized expertise in prostate imaging to maintain diagnostic precision.

Economically, the shorter biparametric scan carries substantial cost-saving potential. Within the UK National Health Service (NHS), the average cost of a full mpMRI prostate scan is approximately £273. The abbreviated bpMRI reduces this to £145 per scan, nearly halving expenditure. This reduction is expected to be even more impactful in healthcare systems with higher baseline imaging costs, such as in the United States, offering a financially sustainable pathway to expand prostate cancer diagnostic services.

Beyond accuracy and cost, the PRIME trial’s results also pave the way for broader systemic change. Prostate Cancer UK is preparing to launch the TRANSFORM trial, the largest prostate cancer screening study in two decades, which will incorporate MRI technology and aim to establish an evidence base for a national prostate cancer screening program. The PRIME findings are a crucial step toward optimizing the MRI component of such screening efforts, ensuring they are both effective and practical.

Dr Matthew Hobbs, Director of Research at Prostate Cancer UK, articulated the transformative potential of these findings, urging regulatory bodies such as NICE (National Institute for Health and Care Excellence) to update their guidelines to accommodate the biparametric MRI approach once further confirmatory evidence is available. Additionally, he encouraged hospitals to prepare adoption by adhering to updated scan quality protocols derived from UCL’s GLIMPSE trial recommendations.

The clinical implications of streamlining prostate MRI are multifaceted. Accelerated scan times mean more men can be served using the existing scanner infrastructure, addressing current disparities in imaging availability. Abandoning contrast-enhanced imaging reduces patient discomfort, minimizes rare risks associated with contrast agents, and decreases the complexity of the procedure. The overall effect is an improved patient experience coupled with enhanced diagnostic throughput.

This study also underscores a broader trend in medical imaging toward tailored, evidence-driven simplification that preserves or enhances diagnostic performance while alleviating logistical burdens. The PRIME trial model combining international collaboration, rigorous methodology, and clinically relevant endpoints exemplifies the pathway for driving practice-changing research in oncological diagnostics.

Future work will focus on further refining biparametric imaging protocols, ensuring reproducibility in diverse clinical environments, and integrating artificial intelligence and advanced image analytics to enhance radiological assessment. These innovations promise to elevate prostate cancer detection rates, reduce unnecessary biopsies, and ultimately improve patient outcomes through earlier and more precise diagnosis.

In summary, the PRIME trial provides compelling evidence that biparametric MRI is a viable, faster, and cost-efficient alternative to the standard multiparametric approach for detecting clinically significant prostate cancer. As the global burden of prostate cancer grows, adopting this streamlined imaging pathway could dramatically improve diagnostic accessibility and efficiency, setting the stage for transformative progress in men’s health worldwide.

Subject of Research: People

Article Title: Biparametric versus multiparametric MRI for prostate cancer diagnosis: The PRIME Diagnostic Clinical Trial

News Publication Date: 10-Sep-2025

Web References:
10.1001/jama.2025.13722 (DOI: http://dx.doi.org/10.1001/jama.2025.13722)

Keywords: Cancer; Prostate cancer; Medical imaging

Prostate cancer remains one of the most commonly diagnosed malignancies in men, and timely, accurate detection is critical for effective treatment planning and improved patient outcomes. Traditionally, multiparametric MRI, which combines several imaging sequences including T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast enhancement, has been considered the gold standard for prostate cancer detection and characterization. While multiparametric MRI offers detailed anatomical and functional data, it is time-intensive, costly, and resource-heavy, often limiting widespread accessibility, particularly in regions with constrained healthcare infrastructure.

The novel biparametric MRI approach eliminates the need for dynamic contrast-enhanced imaging, retaining only T2-weighted imaging and diffusion-weighted imaging, sequences that provide sufficient contrast and functional assessment of prostate tissue. This streamlined scan paradigm not only reduces overall imaging time but also circumvents the use of intravenous contrast agents, mitigating patient risks associated with contrast administration and lowering procedural complexity. Such advancements are expected to enhance patient comfort and reduce barriers to prostate MRI utilization.

Researchers spearheading this investigation have demonstrated that when image quality is sufficient, biparametric MRI can detect clinically significant prostate cancers with accuracy comparable to that of conventional multiparametric MRI. This finding is significant as it challenges long-held assumptions about the necessity of contrast-enhanced sequences for effective prostate cancer diagnosis, opening the door to a new era of efficient, patient-friendly imaging protocols.

One of the most compelling arguments for adopting biparametric MRI lies in its potential to transform global healthcare economics. With an estimated 4 million prostate MRI scans performed annually worldwide, the reduction of scan time per patient could exponentially increase scanner throughput. Such improvements would not only reduce the cost per examination but would also address bottlenecks in imaging services, enhancing access particularly in underserviced areas.

Implementing this abbreviated MRI protocol could also alleviate the growing demand burden on radiology departments, freeing resources to focus on complex cases or other imaging needs. This efficiency gain could be especially impactful in public health systems grappling with limited equipment and trained personnel, enabling more equitable distribution of imaging services.

Beyond simple time savings, the avoidance of gadolinium-based contrast agents aligns with growing concerns over gadolinium deposition in the brain and other tissues. While clinical consequences remain under investigation, reducing patient exposure to contrast agents is widely acknowledged as a favorable safety advancement, particularly for patients requiring repeated imaging exams.

The study’s corresponding author, Dr. Veeru Kasivisvanathan from University College London, emphasized that biparametric MRI’s adoption as a new standard of care hinges on maintaining adequate image quality. Factors such as scanner technology, imaging protocols, and radiologist expertise play critical roles in ensuring reliable diagnostic accuracy. The tissue characterization afforded by the key sequences facilitates precise lesion detection and risk stratification, which are paramount to guiding biopsy decisions or surveillance strategies.

Moreover, the abbreviated MRI approach dovetails with evolving biopsy techniques. When combined with targeted biopsy, biparametric MRI can enhance the diagnostic yield, potentially reducing the number of unnecessary biopsies and associated morbidities. Such synergy between imaging and intervention underscores a holistic shift towards more personalized prostate cancer management.

The researchers have made their study findings available through a prominent medical journal, further encouraging practitioners and policymakers to consider protocol revisions. This evidence-based push towards abbreviated imaging reflects a broader trend in medical imaging towards maximizing diagnostic information while minimizing patient burden and healthcare resource utilization.

If widely embraced, the new biparametric MRI paradigm could revolutionize the diagnostic pathway for men with suspected prostate cancer, leading to earlier detection, quicker treatment initiation, and better overall prognoses. This shift is also anticipated to invigorate healthcare systems by relieving financial and operational pressures, ultimately benefiting a vast patient population on an international scale.

In conclusion, the research heralds a pivotal moment in prostate cancer imaging. By validating a shorter, contrast-free MRI protocol that does not compromise diagnostic efficacy, it challenges existing conventions and paves the way for more accessible, cost-effective, and patient-centric care. The ongoing dialogue within the urological and radiological communities will be critical to refining and integrating this innovation, marking an exciting step forward in cancer diagnostics.

Subject of Research: Prostate cancer diagnosis using abbreviated biparametric magnetic resonance imaging (MRI)

Article Title: Not provided

News Publication Date: Not provided

Web References: Not provided

References: DOI: 10.1001/jama.2025.13722

Keywords: Prostate cancer, Magnetic resonance imaging, Medical diagnosis, Medical tests